Trevi Therapeutics (TRVI)
(Real Time Quote from BATS)
$8.72 USD
+0.26 (3.07%)
Updated Sep 26, 2025 03:38 PM ET
3-Hold of 5 3
C Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRVI 8.72 +0.26(3.07%)
Will TRVI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TRVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRVI
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
TRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
Other News for TRVI
Non-ADX 1,2,3,4 Bullish appears for TRVI after 0.12% move
TRVI forms NR7 on September 25
Narrow Range Bar appears for TRVI after 1.99% move
180 Bullish Setup appears for TRVI after 4.91% move
TRVI falls 4.57% on September 19, leaving the technical picture intact